Middletown, CT, United States of America

Alicia Regueiro-Ren

This inventor holds 46 USPTO granted patents and 25 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in TLR9 Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No.5) Limited, Viiv Healthcare UK (No. 4) Limited. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alicia Regueiro-Ren. Retrieved from https://idiyas.com/inventor/alicia-regueiro-ren

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 46 (Patent Applications = 25)

% Patents Active = 80.4

CIPO Patents = 4 (Patent Applications = 10)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 5.4

ph-index = 8

Forward Citations = 275(Granted Patents)

Location History:

Plainsboro, NJ (US) (2001)
Wallingford, CT (US) (2018 - 2021)
Middletown, CT (US) (2004 - 2022)
New Hope, PA (US) (2021 - 2024)

Company Filing History:

35 out of 3,745

Bristol-Myers Squibb Compnay

patents

7 out of 45

Viiv Healthcare UK (No.5) Limited

patents

4 out of 8

Viiv Healthcare UK (No. 4) Limited

patents

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

TLR9 Inhibitors

Galectin-3

Triterpenoids

HIV Maturation

Antiviral Agents

1H-Pyrrolo Derivatives

Small Molecule Inhibitors

Modified Betulinic Acid

HIV Inhibitors

Diketo-Piperazine

Pharmaceutical Formulations

Indolobenzazepine

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12590091 - 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis (2026-03-31),

2. 12492188 - 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-09),

3. 12486267 - Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-02),

4. 12291522 - Galectin-3 inhibitors (2025-05-06),

5. 12275720 - Small molecule inhibitors of galectin-3 (2025-04-14),

6. 12275719 - Small molecule inhibitors of galectin-3 (2025-04-14),

7. 12275718 - Small molecule inhibitors of galectin-3 (2025-04-14),

8. 12269819 - Small molecule inhibitors of Galectin-3 (2025-04-08),

9. 11970511 - Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors (2024-04-30),

10. 11464790 - Triterpenoids with HIV maturation inhibitory activity (2022-10-11),

11. 11267811 - Small molecule inhibitors of galectin-3 (2022-03-08),

12. 11084845 - C-3 and C-17 modified triterpenoids as HIV-1 inhibitors (2021-08-10),

13. 11072626 - Small molecule inhibitors of Galectin-3 (2021-07-27),

14. 10780102 - Triterpenoids with HIV maturation inhibitory activity (2020-09-22),

15. 10493070 - Azadecalin derivatives as inhibitors of human immunodeficiency virus replication (2019-12-03),

Title: Innovations in Biopharmaceuticals: The Remarkable Contributions of Alicia Regueiro-Ren

Introduction: Alicia Regueiro-Ren, based in Middletown, CT, has made significant strides in the biopharmaceutical sector with an impressive portfolio of 38 patents. These innovations primarily focus on unique compounds that serve as therapeutic agents, highlighting her commitment to advancing medical science.

Latest Patents: Among her latest patents, Alicia has developed "Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors." This work relates to compounds that can inhibit Gal-3, encompassing pharmaceutically acceptable salts and methods for their use. Another noteworthy patent is for "Triterpenoids with HIV maturation inhibitory activity," which describes compounds with unique antiviral properties designed to combat HIV and AIDS.

Career Highlights: Alicia's career includes influential roles at prominent pharmaceutical companies such as Bristol-Myers Squibb Company and ViiV Healthcare UK Limited. Her work at these organizations has been pivotal in not only advancing drug development but also improving patient outcomes.

Collaborations: Throughout her career, Alicia has collaborated with esteemed professionals, including Nicholas A. Meanwell and Jacob Swidorski. These partnerships have facilitated the sharing of ideas and expertise, contributing to the successful development of her innovative compounds.

Conclusion: Alicia Regueiro-Ren's contributions through her patents reflect her dedication to addressing critical health challenges. Her innovative work continues to pave the way for new therapeutic options in the fields of HIV treatment and beyond, solidifying her status as a leading inventor in biopharmaceutical innovation.

Profile summary based on public USPTO records.